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DLC1 = dynein light chain 1; ER = estrogen receptor; HER = human epidermal growth factor receptor; MAPK = mitogen-activated protein kinase;
NF = nuclear factor; PAK = p21-activated serine/threonine kinase; PI-3 = phosphatidylinositol 3; PKA = protein kinase A; VEGF = vascular
endothelial growth factor.
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Introduction
Tumor progression involves the transition of normal cells
into malignant cells through a series of cumulative
alterations. Invasive and migratory properties are acquired
during this process, enabling cells to metastasize (travel to
and grow in tissues far from their origin). Cell proliferation,
cell motility, and cell survival are regulated by multiple
factors, and the changes that occur in cancer cells are the
result of multiple alterations in the cellular signaling
machinery. Successful cell migration depends on the
regulation of the timing of movement, the guidance of
motile cells, and the cytoskeletal and adhesive
characteristic changes within the cells.
The actin cytoskeleton is the primary determinant of cell
shape and motility. The small Rho (p21) GTPases (Rho,
Rac, and Cdc42) have been implicated in multiple steps
during cellular transformation, including regulation of
cytoskeletal reorganization and gene expression [1].
These p21s mediate growth factor-induced morphological
changes that involve actin-based cellular structures. Rho
mediates the formation of cytoskeletal stress fibers and
focal adhesion, Rac mediates the formation of membrane
ruffles and lamellipodia, and Cdc42 mediates the
formation of peripheral filopodia and actin microspikes [1].
Many upstream regulators and downstream effectors of
these small GTPases have been isolated, and their modes
of activation and action have gradually been elucidated.
Mammalian kinases that bind to the GTP-bound forms of
Rho p21s have been identified. These kinases include the
evolutionarily conserved p21-activated serine/threonine
kinase (PAK), which is stimulated by binding to Cdc42
and Rac, and the Rho-binding serine/threonine kinase. In
the present review, we briefly summarize the progress
made in understanding the PAK-family-induced biological
function in breast cancer cells (Fig. 1). Comprehensive
information on PAK family biology, signaling, and
regulation is available in recent reviews [2–5].
The PAK family
Pak1, the first of the PAK family members to be
discovered, was originally cloned from brain tissue as a
p21-interacting kinase that was homologous to yeast
Ste20 [6]. Subsequent identification of five other family
members indicated that this family of protein kinases is
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highly conserved throughout evolution in a variety of
organisms. Although members of this family share
significant homology at the amino acid level, specifically in
the kinase domain, the biological function of each member
is distinct and is dictated by the variable N-terminal
regulatory domain [2].
Although all PAKs interact with GTPases, not all PAKs are
activated by such interaction. GTPase induces activity of
Pak1–Pak3, whereas binding of GTPases to Pak4–Pak6
does not lead to their activation [5]. Lipids can activate
Pak1 either directly or via phosphorylated 3-phospho-
inositide-dependent kinase 1 [3]. In addition, PAKs can be
phosphorylated on various residues by both serine/
threonine kinases like Akt and Cdk5, and also by tyrosine
kinases such as Ab1 and Etk/Bmx [7,8]. Interestingly, the
consensus sequence for Pak1 was deduced based on the
sequence similarity of Pak1 to the catalytic domain of
myosin 1 heavy chain kinase. Phosphorylation of synthetic
substrates containing the consensus phosphorylation site
sequence of myosin 1 heavy chain kinase indicated that
Pak1 also had the same consensus sequence [9].
Activated PAK proteins phosphorylate a variety of
substrates on serine/threonine residues, preferably in the
context of basic residues such as K/R, R/X, X, and S/T, to
bring about cell survival and migration, cytoskeleton
remodeling, and gene regulation. Table 1 presents a list of
known PAK substrates along with the phosphorylation site
sequences. The role of the PAK family members in
cytoskeletal dynamics is well documented [4]. In addition
to playing a role in cytoskeletal changes, PAKs act as
nodal kinases that activate downstream signaling
cascades like mitogen-activated protein kinases, JunN N-
terminal kinase, and NF-κB to bring about a plethora of
cellular responses [2,10].
PAKs in cancer
Emerging evidence suggests that PAK family members
play an important role in cell survival, motility, angio-
genesis, and gene regulation — and thus the PAK family
may constitute a critical signaling nodule during tumor
progression. Early studies indicated that a dominant-
negative PAK mutant inhibits transformation of murine
fibroblasts transformed with several oncogenes including
Ras, Rac1, Cdc42, or Vav3 [11–13]. Pak1 expression
was also increased during malignant progression of
human colorectal carcinoma [14]. Recent findings also
strongly indicate that Pak1 activation is necessary for
lysophosphatidic acid-induced and autotoxin-induced cell
motility in melanoma cells [15]. Furthermore, Pak1 activity
was found to be higher in tumor tissues as compared with
their normal counterparts in head and neck tumors [16]. It
has also been demonstrated that transformation by
Kaposi’s sarcoma-associated herpes virus, which induces
Kaposi’s sarcoma and primary effusion lymphomas,
requires the activation of Pak1 [17]. Results from a large,
combined comparative genomic hybridization array and
tissue microarray analysis have also identified PAK1 as an
Figure 1
p21-activated kinase (PAK) as a signaling nodule in breast cancer cells. Mechanisms of PAK activation and downstream physiological effects of
PAKs are indicated, emphasizing the multiple functions of PAKs in cells. PAKs act upstream of several effectors. The effectors and the outcomes
they influence are shown in this schematic. DLC1, dynein light chain 1; ER, estrogen receptor; MAPK, mitogen-activated protein kinase; PGAM,
phosphoglyceraldehyde mutase; PGM, phosphoglucomutase; VEGF, vascular endothelial growth factor.7
overamplified critical oncogene target with a positive
correlation with cyclin D1 in ovarian carcinomas [18].
In another work, Callow and colleagues [19] analyzed the
roles of Pak4 and Pak6 in human tumorigenesis. In a panel
of cell lines derived from leukemias, melanomas, breast
cancer, colon cancer, lung cancer, liver cancer, ovarian
cancer, and renal cancer, Pak4 was found to be
overexpressed compared with the expression in normal
control tissue in 78% of samples. The authors found that
the Pak4 gene localizes at a region of chromosome 19
that is commonly amplified in a number of human
pancreatic tumors, colon tumors, and ovarian tumors [19].
In addition, an activated allele of Pak4 had transforming
potential while an inactive Pak4 mutant blocked Ras-
dependent anchorage independent growth, further
strengthening the role of Pak4 in tumorigenesis [19].
The status of PAK, possibly Pak2, could also affect the
pathophysiology of the neurofibromatosis type 2 patients.
The neurofibromatosis type 2 tumor-suppressor gene
product Merlin is mutated in the germline of neuro-
fibromatosis type 2 patients and predisposes affected
individuals to intracranial and spinal tumors. In an elegant
investigation, Merlin was demonstrated to be
phosphorylated by PAK at Ser518, a site that affects
Merlin activity and localization [20]. Conversely, Merlin
inhibited Pak1 activation and recruitment to focal
adhesions. The absence of Merlin resulted in
inappropriate activation of Pak1, providing a possible
mechanism for effects seen accompanying loss of Merlin
expression in tumorigenesis [21]. Pak2 was recently
demonstrated to be a negative regulator of myc protein,
suggesting that Pak2 could potentially be used for therapy
to inhibit myc-induced neoplasia [22].
Mouse mammary gland PAK models
Pak1 expression is activated in mammary glands in a
development-dependent manner, with the highest activity
during pregnancy and lactation [23]. Clues about the role
of Pak1 in the mammary gland came from a recent
transgenic model expressing a kinase dead Pak1 mutant.
Inactivation of Pak1 led to incomplete lobulo-alveolar
development and impaired functional differentiation
(Fig. 2a). Interestingly, Pak1 directly interacted with and
phosphorylated Stat5a at Ser779, which was substantially
reduced in transgenic mammary glands, suggesting a role
for Pak1 during alveolar morphogenesis and differentiation
[23]. Pak1 expression and activation has also been linked
with epithelial differentiation during rodent development
[24]. In contrast, persistent activation of Pak1 in mammary
epithelium was accompanied by widespread hyperplasia,
lobulo-alveolar hyperdevelopment during lactation, and
stimulation of the estrogen receptor (ER) target genes
[25]. In addition to Pak1, overexpression of the Rac3
transgene, an upstream activator of Pak1, in mammary
epithelium impaired the normal physiology and led to the
formation of mammary gland lesions [26].
PAK signaling in breast cancer
Since Pak1 was originally thought to be involved in
directional cell motility, and because cell motility is
important for productive metastasis, we initially set out to
search for the role of Pak1 in breast cancer, and
discovered a definitive role of Pak1 in HER2-mediated
increased invasiveness [10]. Subsequent studies
suggested a positive correlation between the expression
and activity of Pak1 and the invasiveness of human breast
cancer cells and breast tumor grades (Fig. 2b) [27,28].
The expression of Pak1 in human breast tumor tissue
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Table 1
Known PAK substrates with their phosphorylation sequence
Phosphorylation 
Substrate sequence Reference
LIMK KRYT [62]
Myosin II light chain RATS [63]
Myosin II light chain kinase GRLS, RPKS [64,65]
Synapsin RXXS [66]
Caldesmon NIKS, GVSS [67,68]
Op18/stathmin KRAS [69]
Merlin KRLS [20]
Filamin A RAPS [70]
Raf-1 QRDS [71]
MEK-1 RPLS [72]
p47phox RRNS [73]
Bad RHSS, RSRS [7,74]
Estrogen receptor KKNS [25]
GEF-H1 RRRS [11]
G z ARRS [75]
Phosphoglycerate mutase-B NRFS, WRRS [76]
Prolactin RRDS [77]
RhoGDI KKQS [78]
Desmin KRAS [67]
Vimentin SSS, RPSS, LRSS, TTS [79]
Histone 3 ARKS [42]
C-terminal binding protein 1 RVQS [35]
Dynein light chain 1 FKS [38]
P41 ARC KDRT [80]
Phosphoglucomutase KVYT [47]
STAT5a ARLS [23]8
correlates with the tumor grade, with higher expression in
less differentiated ductal carcinomas of the breast (grade
III tumors) than in grade II and grade I tumors [29]. Since
Pak1 is downstream of phosphatidylinositol 3 (PI-3)
kinase and PI-3 kinase is negatively regulated by
phosphatase and tensin homolog, some of the high Pak1
activity might result from phosphatase and tensin homolog
inactivation, as has been shown in 11 resected breast
tumors with phosphatase and tensin homolog mutations
[29]. Inhibition of Pak1 using kinase-dead Pak1-K299R in
highly invasive MDA-MB435 breast cancer cells was
associated with excessive cell spreading and
accumulation of mature focal points [30]. A recent study
showed that constitutively activated endogenous PAK is
mislocalized to atypical focal adhesions in the absence of
high levels of activated Rho GTPases [28]. These studies
emphasize the involvement of PAKs in breast cancer
genesis and metastasis.
PAK, a major nodule of growth factor
signaling
Aberrant growth factor signaling is one of the hallmarks of
cancer. The acquisition of an invasive phenotype by
human breast cancer cells has also been attributed to the
stimulation by growth factor signaling. Human epidermal
growth factor receptor (HER) 2 and HER3 expression and
activity have been shown to correlate with breast cancer
progression and prognosis [31]. In breast cancer cells,
Pak1 activity increased in response to heregulin in a PI-3
kinase-dependent manner. Inhibition of HER2 using
herceptin resulted in the blockade of both PI-3
kinase/PAK activation and the formation of actin
structures, further confirming the involvement of Pak1 in
cytoskeletal rearrangements [10].
Highly proliferative human breast cancer-derived cell lines
and tumor tissues have also been shown to contain
hyperactive Rac3 and hyperactive Pak1 and Pak2 [32].
Validation experiments with dominant-negative PAK
mutants revealed the critical significance of the
Rac3–PAK pathway for DNA synthesis and tumor growth
[32]. The PI-3 kinase/Pak1/p38 mitogen-activated protein
kinase (MAPK) pathway has also been shown to be hyper-
activated in breast tumors, and PI-3 kinase and Pak1 are
co-overexpressed in breast tumors [29].
In addition to Pak1 activation by deregulated growth
factors, PAK signaling could also be stimulated by its
upstream activators. For example, high Rac1b expression
has been reported in ductal carcinoma in situ, in primary
breast cancer, and in lymph node metastases, as
compared with benign breast disease. Since many of
these patients with recurrent disease exhibited intense
Rac1b expression at the plasma membrane, it is possible
that Rac1b, and hence its effector PAK, might be
constitutively activated in patients with aggressive breast
cancer [33]. Similarly, PAK interacting exchange factor
(betaPix), an activator of Cdc42/Rac and PAK kinase
activity, was also found to increase membrane ruffling and
to upregulate in human breast cancer tissues [34].
Recent studies also demonstrate that Pak1 phosphory-
lates and blocks the corepressor functions of the C-
terminal binding protein 1 in growth-factor-activated
breast cancer cells [35]. C-terminal binding protein 1 links
the recruitment of DNA-modifying and histone-modifying
proteins to sequence-specific DNA-binding proteins, and
facilitates gene regulation during development and
oncogenesis. C-terminal binding protein 1 phosphory-
lation and inactivation by Pak1 may induce putative genes
by derepression [35]. It may thus be concluded that
aberrant mitogenic signaling in human breast cancers
involve both upstream modulators and downstream
effectors of PAKs.
PAK regulation of cancerous phenotypes
The expression of a catalytically active Pak1 mutant
stimulates anchorage-independent growth of breast
cancer cells in soft agar through a preferential MAPK-
sensitive manner [30]. Interestingly, inhibition of protein
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Figure 2
Known phenotypic changes in mammary epithelium and breast cancer.
(a) Overactivation of p21-activated kinase Pak1 in mouse mammary
gland induced hyperplasia. While the wild-type (WT) mouse mammary
gland has only one single layer of cells (left panel), the mammary gland
of the Pak1-TG mice reveals many layers of cells protruding into the
lumen of alveoli (right panel). (b) Immunohistochemical detection of
Pak1 in normal and breast tumor sections. Left panel, normal section
showing weak cytoplasmic Pak1 expression; right panel, tumor section
showing an intense cytoplasmic staining compared with the normal
section.9
kinase A (PKA) also promotes anchorage-independent
stimulation of the MAPK cascade by growth factors via
PAK [36]. However, PKA has also been shown to
positively regulate Rac1 in growth-factor-activated cells
[37]. It is clear that Pak1-associated cancerous
phenotypes could result from the functional dysregulation
of specific PAK substrates. For example, recent data
showed that dynein light chain 1 (DLC1), a component of
the dynein motor, is a physiological Pak1-interacting
substrate, and that Pak1 phosphorylation of DLC1 at
Ser88 plays a critical role in supporting the growth of
breast cancer cells in an anchorage-independent manner
and in nude mice [38]. Furthermore, DLC1 was
dysregulated in breast cancer samples, and approximately
one-half of the tumors had increased expression of both
Pak1 and DLC1 [38].
PAK and the cell cycle
In lower eukaryotes, Pak1 homologs were demonstrated
to be important in cell cycle events including mitosis,
cytokinesis, and microtubule stabilization [39]. Initial clues
about the role of Pak1 in mammalian cell division came
from studies defining regulated phosphorylation of Pak1 in
fibroblasts and neuronal cells [40,41]. In these studies,
phosphorylation of Pak1 was implicated in cell-cycle
regulation and was shown to affect microtubules in cells
undergoing mitosis. Further support for a definitive role for
Pak1 in the development of chromosomal abnormalities
came from studies where breast cancer cells over-
expressing activated Pak1 exhibited abnormal organization
of mitotic spindles [30].
An unexpected function for Pak1 in mitotic cells was
revealed when Histone H3 was identified as a Pak1
substrate [42]. Pak1 phosphorylates Histone H3.3 on
Ser10, a post-translational modification of Histone H3 that
has been linked with regulation of mitotic chromosomal
assembly, with congregation at the metaphase plate, and
with segregation [42]. The results of this study have
fascinating implications with respect to the role played by
Pak1 in its activated state (as observed in most cancer
cells) on cellular events responsible for incorrect DNA
ploidy of tumor cells. Another study suggested that cyclin
B1/Cdc2 phosphorylates Pak1 in cells undergoing mitosis
[41]. It could thus be speculated that abnormal
segregation of chromosomes during mitosis in tumor cells
results, at least in part, from persistent activation of Pak1
in these cells.
Anti-apoptotic action of PAKs and its
effectors
PAKs promote cell proliferation and survival, presumably
by phosphorylating and inhibiting the pro-apoptotic
protein Bad, caspase-3, caspase-8, and FKHR [43–45].
Phosphorylated Bad demonstrates reduced interaction
with Bcl-2 and Bcl-xL, and demonstrates increased
interaction with 14-3-3 tau. Pak1 activation, and resulting
inactivation of Bad, is also sufficient to antagonize p38
MAPK as well as its upstream activator MKK6-induced
cell death [46]. In addition, Pak1 utilizes its newly
identified substrate, the DLC1, to confer enhanced cell
survival in breast cancer cells, through a mechanism
dependent on Pak1’s phosphorylation of DLC1 on Ser88.
Of specific interest is the Pak1-regulated interaction of
DLC1 with BimL, a BH3-only domain pro-apoptotic
protein. It was shown that Pak1 antiapoptotic function
derive, in part, from its recognition of DLC1-BimL dimers,
which are released upon apoptotic signals from the dynein
motors. Pak1 phosphorylation of both DLC1 and BimL
prevents the ability of BimL to interact and inactivate Bcl-2
[38]. Since cell survival function is dependent on efficient
energy utilization, PAK signaling has now been linked with
components of the glycolytic pathway, phosphoglycer-
aldehyde mutase (reviewed in [2]) and phosphogluco-
mutase [47].
PAK in angiogenesis
Angiogenesis, the growth of new blood vessels from
existing blood vessels, is heavily implicated in tumor
growth and metastasis. Vascular endothelial growth factor
(VEGF) is one of the major players in the process of
angiogenesis. Pak1 signaling is required for VEGF
expression and, consequently, for VEGF function [48]. In
addition, VEGF also signals via Pak1 to bring about its
downstream effects [49]. Specific involvement of Pak1
was confirmed by inhibition of endothelial cell migration by
both dominant-negative Pak1 and an N-terminal proline-
rich Pak1 peptide [50]. Furthermore, heregulin was shown
to upregulate the synthesis of hypoxia-inducible factor 1
alpha, a director activator of VEGF [51]. Since HER2 as
well as Pak1 are known to induce VEGF expression, and
because HER2 signaling stimulates Pak1 activity [10],
these findings suggest that HER2 activation by growth
factors stimulates VEGF expression, presumably via
hypoxia-inducible factor 1 alpha. Recent studies also
indicate that the Rac/PAK pathway is essential for ephrin
A1-mediated inhibition of cell spreading that participates in
blood vessel destabilization, a prerequisite for angio-
genesis [52]. These results further suggest a role for Pak1
in angiogenesis. In contrast, microtubule depolymerization
by agents like vinblastine induced cleavage of Pak2 along
with procaspases, leading to the collapse of the capillary
tube network and endothelial cell apoptosis [53]. This is
an example of distinct functions exhibited by different
members of the PAK family in the cell.
PAK in ER signaling
Human breast cancers and the cell models derived from
them can be classified into those that are steroid hormone
dependent and those that grow independent of estradiol.
An effect of Pak1, which is important for hormone-
dependent breast cancer, is its ability to phosphorylate the
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ER either directly or indirectly. Wang and colleagues
demonstrated that Pak1 phosphorylates the ER at Ser305
and promotes its transactivation (Fig. 3) [25]. Furthermore,
transgenic mice that express kinase-active Pak1 develop
hyperplasia in the mammary epithelium and have
increased expression of ER target genes [23]. In highly
metastatic ER-positive breast carcinomas, the locus to
which PAK has been mapped, 11q13, is amplified [54].
Steroid hormone-independent subtypes often utilize
pathways involving peptide hormones or growth factor.
Since Pak1 could be activated by growth factor signaling,
these findings imply that Pak1 might regulate the ER
pathway in ligand-independent phenotypes.
The consensus phosphorylation motif in the PAK
substrates is not very restricted and is common with other
kinases such as ribosomal S6 kinase [55] and PKA [36].
Consistent with this hypothesis, a recent report showed
that PKA phosphorylation of the ER at Ser305 induces
resistance to tamoxifen [56]. Since the downstream
effects of PKA could be blocked by dominant-negative
Rac1 [37], and because Rac1 is a direct activator of
Pak1, it is tempting to speculate that Pak1 could be
downstream of PKA in affecting the function of the ER.
Current studies are testing this model (S Rayala, R Kumar,
unpublished data). Regardless of the upstream signaling
cascades involved, it is increasingly clear that ER
phosphorylation at Ser305 represents an important
modification for ligand independence and/or tamoxifen
resistance in breast cancer cells.
ER activation by Pak1 also induces upregulation of cyclin
D1 in breast cancer cells, as well as in the mammary
epithelium [57]. In addition, Pak1 could also upregulate
cyclin D1 expression in an ER-independent, but NF-κB-
dependent, manner [57]. In addition, Pak1 has also been
implicated in the induction of cyclin D1 as well as in the
development of resistance to AND34/BCAR3, an
upstream activator of Pak1 [58]. These findings suggest
that Pak1 could potentially regulate cyclin D1 expression in
both ER-positive and ER-negative breast cancer cells
(Fig. 3). Another of the PAK family members known to
interact with nuclear receptors is Pak6, which interacts
with ER; 4-hydroxytamoxifen enhances their interaction
[59]. The ability of PAK members to interact with steroid
hormonal receptors suggests that PAKs may play an
important role in the cross-talk between steroid hormone
receptors and growth factor signaling pathways.
Therapeutic implication of PAK research
Since PAK signaling is important in the process of
tumorigenesis, any interference with PAK and/or one of its
critical downstream substrates may be a useful
therapeutic approach. Use of dominant-negative
expression plasmids of Pak1 controls the metastasis of a
number of types of tumor cells [10,39]. Because Pak1 is a
pro-survival signal in cells, interfering with its activity and
signaling should induce apoptosis in tumors, leading to
tumor regression. Nheu and colleagues [60] have recently
developed a first generation of compounds that target the
activity of PAKs. Two synthetic derivatives of an adenosine
triphosphate antagonist, CEP-1347 and KT D606, target
PAKs and inhibit the growth of transformed murine
fibroblasts. The recent elucidation of the Pak1 crystal
structure [61] should aid the development of specific
Pak1 inhibitors. A recent study identified a small peptide
that can interfere with Nck binding to Pak1, which can
interfere with angiogenesis [48], suggesting that small
molecule interference of PAK interaction with its binding
proteins may have some therapeutic value.
Since Pak1 represents a common convergence nodule of
receptor tyrosine kinases, PI-3 kinase–AKT, Ras, small
GTPases, and lipid signaling, the impact of Pak1 signaling
on the biology of cancer cells is not limited to breast
cancer (with the exception of ER regulation). Hence,
lessons from breast cancer model systems are applicable
to other cancer types and should aid in the development
of targeted anticancer therapies.
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Figure 3
A schematic model of p21-activated kinase (PAK) action in the
absence of estrogen in breast cancer cells. A simplified summary of
the cellular events in which regulation of cancer-related events by
PAKs has been implicated. Both the N-termini and C-termini of PAK
can interact with various signaling components and thus promote
specific changes required for cells to acquire a cancerous and
metastatic phenotype. Broken lines, proposed regulation. ER, estrogen
receptor; PKA, protein kinase A.11
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